MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment

Kaboli, Parham Jabbarzadeh; Rahmat, Asmah; Ismail, Patimah; Ling, King-Hwa

doi:10.1016/j.phrs.2015.04.015

Cited by 119 publications

(79 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Owing to their crucial roles in regulating multiple cancerrelated pathways, miRNAs have been actively investigated for clinical application and therapeutic intervention [242]. The current approach for developing miRNA-based therapeutics is through the administration of a synthetic anti-miRNA or a miRNA-mimic oligonucleotide [242].…”

Section: Ncrnas As Therapeutic Targetsmentioning

confidence: 99%

See 1 more Smart Citation

Noncoding RNAs in breast cancer

Lo¹,

Wolfson²,

Zhou³

et al. 2015

Briefings in Functional Genomics

View full text Add to dashboard Cite

The mammalian transcriptome has recently been revealed to encompass a large number of noncoding RNAs (ncRNAs) that play a variety of important regulatory roles in gene expression and other biological processes. MicroRNAs (miRNAs), the best studied of the short noncoding RNAs (sncRNAs), have been extensively characterized with regard to their biogenesis, function and importance in tumorigenesis. Another class of sncRNAs called piwi-interacting RNAs (piRNAs) has also gained attention recently in cancer research owing to their critical role in stem cell regulation. Long noncoding RNAs (lncRNAs) of >200 nucleotides in length have recently emerged as key regulators of developmental processes, including mammary gland development. lncRNA dysregulation has also been implicated in the development of various cancers, including breast cancer. In this review, we describe and discuss the roles of sncRNAs (including miRNAs and piRNAs) and lncRNAs in the initiation and progression of breast tumorigenesis, with a focus on outlining the molecular mechanisms of oncogenic and tumor-suppressor ncRNAs. Moreover, the current and potential future applications of ncRNAs to clinical breast cancer research are also discussed, with an emphasis on ncRNA-based diagnosis, prognosis and future therapeutics.

show abstract

Section: Ncrnas As Therapeutic Targetsmentioning

confidence: 99%

“…The current approach for developing miRNA-based therapeutics is through the administration of a synthetic anti-miRNA or a miRNA-mimic oligonucleotide [242]. To improve the therapeutic efficacy, Lennox et al [243] conjugated a novel compound, N,Ndiethyl-4 -(4-nitronaphthalen-1-ylazo)-phenylamine, to these [239]…”

Section: Ncrnas As Therapeutic Targetsmentioning

confidence: 99%

Noncoding RNAs in breast cancer

Lo¹,

Wolfson²,

Zhou³

et al. 2015

Briefings in Functional Genomics

View full text Add to dashboard Cite

show abstract

“…In addition, miRNA were recently studied as biological biomarkers in breast cancer, specifically for diagnosis, predicting cancer behavior and outcome [20].…”

Section: Gene Expression Profiling Of Breast Cancermentioning

confidence: 99%

Molecular Fingerprints and Biomarkers of Breast Cancer

Kamel¹,

Al-Amodi²,

Elmoneim³

2017

Breast Cancer - From Biology to Medicine

View full text Add to dashboard Cite

Substantial progress has been made over the past three decades in understanding breast cancer (BC) molecular biology, genomics, and targeted therapy. The recent comprehensive molecular and pathological diversity observed in BC patients indicates that BC is not a homogeneous disease; It may be appropriately defined as a myriad of diseases. The explosion of molecular information in the past 10 years has led to a better understanding of the biologic diversity of breast cancers (BCs), and clues to the different etiologic pathways to BC development. It will be useful to study the epigenetics of BC cells and define the mechanisms of both genetic and epigenetic driving alterations beside the mutations. Identifying the oncogenes and tumor suppressor genes is the purpose cancer diagnostics and therapeutics. Oncogenes as well as novel ones involved in the significantly altered regions would enable researchers to identify new causes and molecular pathways that may be targeted at BC treatment. Our main goal is to provide comprehensive understanding of underlying molecular mechanisms and hallmarks of BC, focusing on the identification of fingerprints and novel molecular targets that will greatly improve the cancer predictive, prognostic, and diagnostic biomarkers and, in addition, the possible targets for novel therapies.

show abstract

Section: Perspectives and New Directionsmentioning

confidence: 99%

“…Deeper molecular understanding of tRF-YB-1 binding will allow the development of diagnostic and therapeutic tools based on tRNA fragments. Future studies will also determine whether tiRNAs can join the ranks of microRNAs in the regulation of mRNA translation in health and disease (90,91).Looking into the future, the prospect of applying ANG-induced tRNA halves in the treatment of neurodegenerative diseases such as ALS is particularly exciting. ALS, often referred to as Lou Gehrig disease in the United States, is a paralyzing and ultimately fatal disease characterized by the progressive loss of motor neurons (92).…”

mentioning

confidence: 99%

The Many Virtues of tRNA-derived Stress-induced RNAs (tiRNAs): Discovering Novel Mechanisms of Stress Response and Effect on Human Health

Saikia

Hatzoglou

2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

In mammalian cells, mature tRNAs are cleaved by stress-activated ribonuclease angiogenin to generate 5-and 3-tRNA halves: a novel class of small non-coding RNAs of 30 -40 nucleotides in length. The biogenesis and biological functions of tRNA halves are emerging areas of research. This review will discuss the most recent findings on: (i) the mechanism and regulation of their biogenesis, (ii) their mechanism of action (we will specifically discuss their role in the protein synthesis inhibition and the intrinsic pathway of apoptosis), and (iii) their effects on the human physiology and disease conditions. Recent breakthroughs in high-throughput sequencing have led to a more comprehensive view of the cellular transcriptome. We are now aware of numerous additional non-protein-coding RNA (ncRNA) 3 candidates in all three domains of life, thus indicating a hidden layer of transcriptome complexity (1, 2). A more recent development in our understanding of the complexity of cellular RNomes arose with the exciting discovery that ncRNA transcripts with well described functions, such as the tRNAs, can serve as precursors for downstream cleavage events, generating yet another class of functional RNA fragments. Two major classes of tRNA fragments have been identified in human cells. The 17-26-nucleotide long tRNA-derived RNA fragments (tRFs) are products of precise processing at the 5Ј-or 3Ј-end of mature or precursor tRNAs. The tRF-5 and tRF-3 are derived from terminal ends of mature tRNAs, whereas tRF-1 are 3Ј-trailer sequences of pre-tRNAs (3). The other important class of tRNA fragments found in mammalian cells and tissues is the tRNA-derived stress-induced RNAs (tiRNAs). tiRNAs were first reported in human fetus hepatic tissue (4) and human osteosarcoma cells (U2OS), respectively (5). tRFs and tiRNAs are the newest members of the cellular ncRNA repertoire that are found in several organisms and play prominent roles in various cellular functions (6). These tRNA fragments can be generated in cells under physiological conditions and also produced as part of the cellular stress response (4 -9). In mammalian cells, tiRNAs are produced by the cleavage of mature tRNAs at positions close to the anticodon, giving rise to the 30 -40-nucleotide-long 5Ј-and 3Ј-tRNA halves, a term used interchangeably with 5Ј-and 3Ј-tiRNAs throughout this review. The enzyme responsible for this endonucleolytic cleavage is angiogenin (ANG) (4,5). ANG is a member of the pancreatic RNase superfamily distinguished by its potent in vivo angiogenic activity as well as its prominent role in cancer development and neurodegeneration (10, 11). Here we will review the ANG-induced tRNA halves (tiRNAs), their role in mammalian stress response mechanisms, and other cellular functions. Additionally, we will discuss their potential implications in the pathobiology of human diseases with a special focus on neurodegenerative disorders. ANG-induced tRNA Cleavage in Mammalian CellsEndonucleolytic cleavage of mammalian tRNAs by ANG was reported by two research groups in...

show abstract

MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment

Cited by 119 publications

References 160 publications

Noncoding RNAs in breast cancer

Noncoding RNAs in breast cancer

Molecular Fingerprints and Biomarkers of Breast Cancer

The Many Virtues of tRNA-derived Stress-induced RNAs (tiRNAs): Discovering Novel Mechanisms of Stress Response and Effect on Human Health

Contact Info

Product

Resources

About